Drug Profile

MIV 802

Alternative Names: ASC 21; MIV-802; Nucleotide polymerase inhibitor - Medivir AB

Latest Information Update: 07 Dec 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novadex Pharmaceuticals
Developer Medivir AB
Class Antivirals; Small molecules
Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleotidyltransferase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis C

Most Recent Events

01 Oct 2020 MIV 802 is no longer licensed to Ascletis in China, Hong Kong, Taiwan and Macau
01 Oct 2020 Discontinued - Preclinical for Hepatitis C in Sweden (unspecified route) due to lack of commercial potential in hepatitis C
04 Jan 2019 Preclinical development is ongoing in Sweden in Hepatitis C (Medivir pipeline, January 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com